AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
The original release is unavailable here.
Story so far
- AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
- AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
- AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
Earlier from AN2 Therapeutics
- AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
- AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
- AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
- AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
- AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Later from AN2 Therapeutics
- AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
- AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
- AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
- AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
- AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
Follow AN2 Therapeutics into a list and get an email when it puts out news.
Follow AN2 Therapeutics